15 Apr, 2022 Could the Specter of March-In Rights Finally Impact Drug Pricing Reform? By Kristen Riemenschneider Joshua Samuel On March 24, 2022 a group of public interest organizations filed a petition urging the Department of Health and Human Services (“HHS”) to...
24 Jan, 2022 Is it time for big biopharma companies to rethink the use of federal funding for R&D? By Kristen Riemenschneider This article was originally published in STAT on January 18, 2022. I have been negotiating with representatives of the federal government...